The United Kingdom and the United States have forged a landmark commercial pact that will guarantee zero duties on British pharmaceutical products being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase expenditure on medicines through the National Health Service (NHS). This commitment ensures that import taxes on these key exports will remain at zero for a duration of the next three years.
This development is in response to recent threats to dramatically increase tariffs on branded drug products, with increases floated up to one hundred percent.
"This arrangement with the UK strengthens the global environment for cutting-edge drugs and brings long-overdue fairness to transatlantic drug exports," a release declared.
Trade Significance
Drugs are one of the the United Kingdom's largest exports to the United States, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months leading up to the third quarter, the UK exported drugs valued at billions to the US. This figure made up nearly one-fifth of total UK exports in that period.
"This agreement protects work, stimulates investment and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Specific NHS Changes
The agreement involves several specific pledges from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to double total public funding on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The sum drug companies must pay back to the NHS to stay within budget will be restricted at 15%. Last year, refunds exceeded twenty percent.
Industry Background
The deal follows a ongoing tension between the sector and the ministers over medicine costs and approval rates.
These tensions were intensified by arguments that US patients were paying several times more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been paused or scrapped, while substantial funding commitments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
